BEO-101

BEO-101 is a potent, selective, and orally bioavailable small-molecule inhibitor of B-cell lymphoma 2 (BCL-2), developed by BeOne Medicines AG. It is specifically engineered to target the BH3-binding groove of the BCL-2 protein, thereby preventing it from sequestering pro-apoptotic proteins and triggering programmed cell death (apoptosis) in malignant B-cells. BEO-101 is being developed for the treatment of relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML). The compound aims to overcome resistance mechanisms associated with first-generation BCL-2 inhibitors and improve the therapeutic window for patients with hematologic cancers.

Other names

N-[4-({[(1R,4R)-4-hydroxy-4-methylcyclohexyl]methyl}amino)-3-nitrobenzene-1-sulfonyl]-4-(2-{(2S)-2-[2-(propan-2-yl)phenyl]pyrrolidin-1-yl}-7-azaspiro[3.5]nonan-7-yl)-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide